A chromatin regulator-related gene signature was calculated, and this signature provides the strong independent predictive capability for clinical prognosis and immunotherapy efficacy for patients  …

In a collaboration between the partner sites Heidelberg and Dresden of the National Center for Tumor Diseases (NCT) a blood extracellular-vesicle-transported mRNA signature to discriminate…

As part of the NEURO-ONCOLOGY WORKING GROUP (NOA) in the German Cancer Association (DKG) we had the pleasure to moderate a webinar on fundamentals, current…

The findings suggest a dynamic relationship between MYC amplification and innate immune suppression in MYC amplified neoplasms and support further investigation of phagocytosis modulation as…

Accreditation approved to participate in European network on 3R - Replace, Refine, Reduce animal research. Excited to participate in WG1 on "Quality and Translatability of…

MET F/SVs but not genomic amplification, were highly enriched in the secondary glioblastomas (sGBM) and marked worse prognosis. Further molecular and scRNA-seq analysis revealed that…

Data Prevalence is defining co-founder in statistics. Thanks for your visit Dr. Klimova from NCT partner site Dresden.

November 2022: Invited talk at NOA Annual Meeting in Kopfklinik University Medical Center Heidelberg. Interesting to learn about the Alcatraz concept of cancer therapy.

October 2022: Invited talk Nano2Clinic Final conference @ La Sapienza, Rome. Great progress towards position paper on innovation for future drug development and new COST…

New publication with participation of our team on the transcription factor ZEB1 and its potential as therapeutic target in neuroinflammatory diseases.